Diagnosis and Management of Classica Homocystinuria in Brazil: A Summary of 72 Late-Diagnosed Patients
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT)
Autores
POLONI, Soraia
HOSS, Giovana W.
SPERB-LUDWIG, Fernanda
BORSATTO, Taciane
DORIQUI, Maria Juliana R.
LEÃO, Emília K.E.A
BOA-SORTE, Ney
LOURENÇO, Charles M.
SOUZA, Carolina F. M. de
Citação
JOURNAL OF INBORN ERRORS OF METABOLISM AND SCREENING, v.6, n.0, p.e180007, 2019
Resumo
Abstract This study described a broad clinical characterization of classical homocystinuria (HCU) in Brazil. This was a cross-sectional, observational study including clinical and biochemical data from 72 patients (60 families) from Brazil (South, n = 13; Southeast, n = 37; Northeast, n = 8; North, n = 1; and Midwest, n = 1). Parental consanguinity was reported in 42% of families. Ocular manifestations were the earliest detected symptom (53% of cases), the main reason for diagnostic suspicion (63% of cases), and the most prevalent manifestation at diagnosis (67% of cases). Pyridoxine responsiveness was observed in 14% of patients. Only 22% of nonresponsive patients on treatment had total homocysteine levels <100 mmol/L. Most commonly used treatment strategies were pyridoxine (93% of patients), folic acid (90%), betaine (74%), vitamin B12 (27%), and low-methionine diet + metabolic formula (17%). Most patients diagnosed with HCU in Brazil are late diagnosed, express a severe phenotype, and poor metabolic control. Milder forms of HCU are likely underrepresented due to underdiagnosis.
Palavras-chave
classical homocystinuria, CBS deficiency, homocysteine, pyridoxine responsiveness, diagnosis
Referências
- Adam S, 2013, MOL GENET METAB, V110, P454, DOI 10.1016/j.ymgme.2013.10.003
- Blom HJ, 2011, J INHERIT METAB DIS, V34, P75, DOI 10.1007/s10545-010-9177-4
- CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505
- Chieffi AL, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2430-x
- De Moura RR, 2015, AM J HUM BIOL, V27, P674, DOI 10.1002/ajhb.22714
- El-Said MF, 2006, HUM MUTAT, V27, P719, DOI 10.1002/humu.9436
- GALLAGHER PM, 1995, HUM MUTAT, V6, P177, DOI 10.1002/humu.1380060211
- Gupta S, 2016, J INHERIT METAB DIS, V39, P39, DOI 10.1007/s10545-015-9883-z
- Huemer M, 2015, J INHERIT METAB DIS, V38, P1007, DOI 10.1007/s10545-015-9830-z
- Kehdy FSG, 2015, P NATL ACAD SCI USA, V112, P8696, DOI 10.1073/pnas.1504447112
- Kopecka J, 2011, J INHERIT METAB DIS, V34, P39, DOI 10.1007/s10545-010-9087-5
- Lawson-Yuen A, 2006, MOL GENET METAB, V88, P201, DOI 10.1016/j.ymgme.2006.02.004
- Magner M, 2011, J INHERIT METAB DIS, V34, P33, DOI 10.1007/s10545-010-9146-y
- Majtan T, 2017, FASEB J, V31, P5495, DOI 10.1096/fj.201700565R
- Moorthie S, 2014, J INHERIT METAB DIS, V37, P889, DOI 10.1007/s10545-014-9729-0
- Morris AAM, 2017, J INHERIT METAB DIS, V40, P49, DOI 10.1007/s10545-016-9979-0
- MUDD SH, 1985, AM J HUM GENET, V37, P1
- Mudd SH, 2001, The metabolic and molecular bases of inherited disease
- Naughten ER, 1998, EUR J PEDIATR, V157, pS84, DOI 10.1007/PL00014310
- Poloni S, 2018, MOL GENET GENOM MED, V6, P160, DOI 10.1002/mgg3.342
- Singh LR, 2007, MOL GENET METAB, V91, P335, DOI 10.1016/j.ymgme.2007.04.011
- Skovby F, 2010, MOL GENET METAB, V99, P1, DOI 10.1016/j.ymgme.2009.09.009
- Stipanuk MH, 2011, J INHERIT METAB DIS, V34, P17, DOI 10.1007/s10545-009-9006-9
- Stopa Sheila Rizzato, 2017, Rev. Saúde Pública, V51, p3s, DOI [10.1590/S1518-8787.2017051000074, 10.1590/s1518-8787.2017051000074]
- Woods E, 2017, BMJ Case Rep
- Yap S, 2000, SEMIN THROMB HEMOST, V26, P335, DOI 10.1055/s-2000-8100
- Yap S, 1998, J INHERIT METAB DIS, V21, P738, DOI 10.1023/A:1005445132327
- Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225
- Yap S, 2001, J INHERIT METAB DIS, V24, P437, DOI 10.1023/A:1010525528842
- Zschocke J, 2009, HUM MUTAT, V30, P1021, DOI 10.1002/humu.20994